2013
DOI: 10.3109/14756366.2013.837898
|View full text |Cite
|
Sign up to set email alerts
|

Design, synthesis and biological evaluation of 2-aminopyrimidinones and their 6-aza-analogs as a new class of CK2 inhibitors

Abstract: In order to find the new potent CK2 inhibitors the 60 derivatives of 2-aminopyrimidinone and their 6-aza-substituted analogs were synthesized and tested in vitro. Among them, the most efficient inhibitor 2-hydroxy-5-[4-(4-methoxyphehyl)-6-oxo-1,6-dihydropyrimidin-2-ylamino] benzoic acid was identified (IC 50 ¼ 1.1 mM). The structure-activity relationship study of newly synthesized derivatives was carried out and their binding mode with adenosine triphosphateacceptor site of CK2 was proposed.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2014
2014
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 30 publications
(32 reference statements)
0
1
0
Order By: Relevance
“…The reported ATP-noncompetitive CK2 inhibitors provide opportunities for the development of allosteric inhibitors, 18,19 which target the CK2b subunit or CK2a-CK2b interaction. As for the ATP-competitive inhibitors, several classes of them have been discovered, [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] such as tetrabromo-1H-benzotriazole (TBB), 38 coumarin derivatives, 39 emodin, 40 (5-oxo-5,6dihydroindolo[1,2-a]quinazolin-7-yl) acetic acid (IQA), 40 and pyrazolo [1,5-a] [1,3,5]triazine derivatives, 41 for representative examples. However, due to limited selectivity, potency or possible potential long-term toxicity, none of the above compounds have reached clinical trials.…”
Section: Introductionmentioning
confidence: 99%
“…The reported ATP-noncompetitive CK2 inhibitors provide opportunities for the development of allosteric inhibitors, 18,19 which target the CK2b subunit or CK2a-CK2b interaction. As for the ATP-competitive inhibitors, several classes of them have been discovered, [20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36][37] such as tetrabromo-1H-benzotriazole (TBB), 38 coumarin derivatives, 39 emodin, 40 (5-oxo-5,6dihydroindolo[1,2-a]quinazolin-7-yl) acetic acid (IQA), 40 and pyrazolo [1,5-a] [1,3,5]triazine derivatives, 41 for representative examples. However, due to limited selectivity, potency or possible potential long-term toxicity, none of the above compounds have reached clinical trials.…”
Section: Introductionmentioning
confidence: 99%